Skip to content

Ultrafast versus Standard Vitrification/Warming on Post-Warming Blastocyst Outcomes: A Randomized Controlled Trial

Ultrafast versus Standard Vitrification/Warming on Post-Warming Blastocyst Outcomes: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500106903
Enrollment
Unknown
Registered
2025-07-31
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Interventions

Test Group 1:Ultra-fast vitrification freezing + ultra-fast glass defrosting
Control group:Vitrification Media Kit,Warming Media Kit
Test Group2:Vitrification Media Kit,Warming Media Kit

Sponsors

The first people's Hospital of Yunnan Province
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Female study participants are 20 years old=2 according to the Gardner blastocyst grading criteria (assessed on the day of enrollment); 3. Indications for in vitro fertilization-embryo transfer (IVF-ET) or intracytoplasmic sperm microinjection technology (ICSI); 4. Endometrial preparation plan uses hormone replacement therapy (HRT) cycle; 5. Blastocysts need to be thawed and transferred; 6. Both husband and wife have normal chromosomes, and use autologous germ cells for assisted reproduction.

Exclusion criteria

Exclusion criteria: 1. History of 2 or more adverse pregnancy attempts; 2. Severe adenomyosis, endometriosis stage III or VI; 3. Hydrosalpinx effusion; 4. There are uterine abnormalities that affect pregnancy outcomes, such as malformed uterus (unicornuate uterus, mediastinal uterus, bicornuate uterus, double uterus), endometrial polyps, type 0~II uterine fibroids or larger uterine fibroids (=4cm), uterine adhesions, endometrial thickness <8cm on HCG day or transplantation day; 5. Systemic diseases such as reproductive tuberculosis, uncontrolled thyroid dysfunction, diabetes, hypertension, etc.; 6. Those who are not suitable for inclusion according to the investigator's judgment.

Design outcomes

Primary

MeasureTime frame
Blastocyst survival rate;

Secondary

MeasureTime frame
Clinical pregnancy rate;ß-HCG positive rate;Implantation rate;Operational efficiency (operation time for vitrification and warming);

Countries

China

Contacts

Public ContactYonggang Li

The first people's Hospital of Yunnan Province

756029726@qq.com+86 137 0841 2682

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026